BioMarin raises 2026 revenue forecast to $3.825-$3.925B after Amicus acquisition boosts growth

BioMarin Pharmaceutical reported Q1 2026 revenues of $766 million, up 3% year-over-year, driven by increased demand for enzyme therapies and new patients on VOXZOGO. Following its acquisition of Amicus Therapeutics, BioMarin raised its full-year 2026 revenue guidance to $3.825-$3.925 billion, reflecting a 20% growth rate at the midpoint. The company highlighted strong pipeline progress, including FDA approvals and upcoming Phase 3 data readouts, positioning it for continued innovation and growth. Despite higher expenses related to the acquisition and R&D, BioMarin expects improved financial performance and expanded patient reach in rare diseases.